Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9

Cancer Immunology, Immunotherapy

Volumn 63, Issue 4, 2014, Pages 357-367

  Zhang, Yuyi ^a   Lin, Ang ^a   Zhang, Cai ^a   Tian, Zhigang ^a   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; CpG ODN; Human hepatocellular carcinoma; TLR9

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 6; INTERLEUKIN 8; OND M 362; OND M362; PHOSPHOROTHIOIC ACID; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CPG ISLANDS; CYTOKINES; FEMALE; HUMANS; LIVER NEOPLASMS; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SPECIFIC PATHOGEN-FREE ORGANISMS; TOLL-LIKE RECEPTOR 9; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896495897     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1518-y     Document Type: Article

References (45)

1. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY (2008) Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14(16):5124-5130
2. Sun X, Zhang J, Wang L, Tian Z (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262(2):201-213
3. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805-820
4. Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327:291-295
5. Beutler B (2009) Microbe sensing positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 227:248-263
6. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9:57-63
7. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009-5014 (Pubitemid 40827306)
8. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102-106
9. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z (2002) Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101:415-422
10. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS (2007) Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67:774-781 (Pubitemid 46709446)
11. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4:437-447 (Pubitemid 44197039)
12. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859-3868
13. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP (2003) Endotoxin/lipopolysaccharide activates NF=kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 170:795-804 (Pubitemid 36070531)
14. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ (2003) AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278:23432-23440 (Pubitemid 36830160)
15. Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, Wong LY, Klumpp DJ, Thumbikat P (2008) The toll-like receptor pathway: a novel mechanism of infection induced carcinogenesis of prostate epithelial cells. Prostate 68: 223-229 (Pubitemid 351186234)
16. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL (2009) Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105-3113
17. Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M (2010) Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 70:9816-9826
18. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D (2011) Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71:2466-2475
19. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R (2006) Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5:1585-1592 (Pubitemid 44070496)
20. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, Puybasset L, Van Effenterre R, Delattre JY, Carpentier AF (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8:60-66 (Pubitemid 43154452)
21. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Investig 117:1184-1194
22. Zhang J, Sun R, Wei H, Zhang J, Tian Z (2004) Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 89:338-347 (Pubitemid 38788420)
23. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G (2008) Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 27:225-233
24. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27:218-224
25. Yoneda K, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Fuke H, Yamamoto N, Masuya M, Horie R, Uchida K, Takei Y (2008) Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 33:929-936
26. Tanaka J, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K, Kojima T, Takei Y (2010) Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 37:805-814
27. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Kreig AM (1993) Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53-66 (Pubitemid 23152125)
28. Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ (2000) Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol 165:4165-4173
29. +T cells through a TLR9-and MyD88-independent mechanism. J Immunol 187:3033-3043
30. Akhtar M, Watson JL, Nazli A, McKay DM (2003) Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent NF-kappaB-independent pathway. FASEB J 17:1319-1321
31. + cells via mitogen-activated protein kinase-dependent and NF-kappaB-independent pathways. Int Immunol 17:1525-1531
32. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L (2007) Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 6:1704-1709 (Pubitemid 351590304)
33. Ma L, Zhao G, Hua C, Li X, Zhao X, Sun L, Hou Y (2009) Down-regulation of TLR9 expression affects the maturation and function of murine bone marrow-derived dendritic cells induced by CpG. Cell Mol Immunol 6:199-205
34. Muhonen P, Avnet S, Parthasarathy RN, Janckila AJ, Halleen JM, Laitala-Leinonen T, Väänänen HK (2007) Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules. Biochem Biophys Res Commun 359:889-895 (Pubitemid 46957541)
35. Sano K, Shirota H, Terui T, Hattori T, Tamura G (2003) Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. J Immunol 170:2367-2373 (Pubitemid 36245623)
36. El Kebir D, József L, Filep JG (2008) Neutrophil recognition of bacterial DNA and Toll-like receptor 9-dependent and -independent regulation of neutrophil function. Arch Immunol Ther Exp (Warsz) 56:41-53 (Pubitemid 351651405)
37. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A, Fung-Leung WP, Colonna M, Karlsson L (2006) CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 172:1057-1068
38. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL (2004) Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 190:1841-1849 (Pubitemid 39487831)
39. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10:187-192 (Pubitemid 38524890)
40. Shen H, Iwasaki A (2006) A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide. J Clin Investig 116:2237-2243 (Pubitemid 44162333)
41. Cammarota M, De Rosa M, Stellavato A, Lamberti M, Marzaioli I, Giuliano M (2009) In vitro evaluation of Lactobacillus plantarum DSMZ 12028 as a probiotic: emphasis on innate immunity. Int J Food Microbiol 135(2):90-98
42. Han Q, Zhang C, Zhang J, Tian Z (2011) Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 54(4):1179-1189
43. Díez S, Navarro G, de ILarduya CT (2009) In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med 11(1):38-45
44. Cho HA, Park IS, Kim TW, Oh YK, Yang KS, Kim JS (2009) Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch Pharm Res 32(7):1077-1086
45. Hu Y, Li K, Wang L, Yin S, Zhang Z, Zhang Y (2010) Pegylated immuno-lipopolyplexes: a novel non-viral gene delivery system for liver cancer therapy. J Control Release 144(1):75-81